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Rx odds ratio p value 95% C.I.
A+B 197 0.51 <0.01 033-0.79
A+B+C 558 0.58 <0.01 0.42-0.81
B 429 0.66 003 0.46-095
B+C 794 0.7 002 052-0.95
A+C 291 0.96 081 0.67-137
A 197 1.16 0.47 0.78-1.72
None 832 1.88 <0.001 1.42-250
MI
All
WMI not available
WMI>1.2
WMI:51.2
WM I :5 1.2 Randomised
WMI < 1.2 Excluded
n
7001
475
3920
2606
1747
859
1 year mortality
23± 1%
50±4%
12± 1%
34± 2%
24± 1%
54±3%
Rx with A in combination with 8 significantly improves mortality when com-
pared to Rx with C even after controlling for CHF Significant differences in
the prevalence of CH F in various Rx groups (53% in A and 5% in Band 11 %
in C) and inability to adequately control for the severity of CHF may explain
the observed effect of Rx with A alone. Conclusions: Combination Rx with A
and 8 is preferable to Rx with Calone. It appears that mortality benefit ofACE
Inhibition in patients with CAD is not limited to patients who have CHF
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1787-31 Efficacy and Safety of Early Administration of
Intravenous Enalaprllat in Congestive Heart Failure
Patients with Acute Pulmonary Edema
Djillali Annane, Eric Bellissant, Eric Pussard, Roland Asmar, Florence Lacombe,
Olivier Madonna, Michel Safar, Jean-Fran~ois Giudicelli, Philippe Gajdos.
Reanimation Medicafe, H6pital R. Poincare, Garches, France
The systemic (Swan-Ganz cathet r, brachial sphygmomanometer) and EIl-
gional (20 pulsed doppler, paraaminohippurate and indocyanine green clear-
ances) hemodynamic and blood gases effects of a single intravenous 2-h-
infusion of 1 mg enalaprilat (E) were investigated within the 12 h following
an acute pulmonary edema episode and compared to those of a placebo (P)
in a randomized double-blind study performed in 20 CHF 11I1-IV NYHA) pa-
tients. The effects were investigated before and 2, 4 and 8 h after the onset
of treatment infusion. At peak effect, and as compared to P, E significantly
decreased pulmonary wedge pressure (-37 vs -10%, P = 0.001), diastolic
and mean systemic (-21 vs -4%, P = 0.009, -18 vs -6%, p ~ 0.026) and
pulmonary (-21 vs -8%, p = 0.040, -18 vs -9%, p = 0.046) arterial pres-
sures, brachial and renal resistances (-44 vs -14%, P = 0.017, -22 vs -2%,
P = 0.014) and significantly increased brachial and renal blood flows (+ 77
vs +8%, P = 0.036, + 12 vs 0%, p = 0.043) arterial oxygen tension (+ 2 vs
-8%, P = 0.041) and saturation (+ 1vs -2%, P = 0.045) and finally tended to
improve intra-pulmonary shunt (-18 vs -16%, P = 0.080). Simultaneously,
E did not affect heart rate, cardiac output, systolic systemic and pulmonary
arterial pressures, and carotid and hepato-splanchnic hemodynamics. Time
courses of plasma electrolytes, creatinine and nitrogen clearances were not
significantly different between E and P. We conclude that in this study early
administration of intravenous enalaprilat was effective and well tolerated in
CHF patients with acute pulmonary edema.
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1787-41 The Paradox of Low Risk Among High Risk Patients
in Controlled Trials - Experience In the TRAndolapril
Cardiac Evaluation Trial
Lars K"ber, Christian Torp-Pedersen, TRACE study group. Gentofte University
Hospital, Copenhagen, Denmark
Mortality in epidemiological studies is almost always larger than in appar-
ently similar populations selected for a clinical trial. To study this problem,
patient inclusion was tracked very carefully in the Trandolapril Cardiac eval-
uation (TRACE) trial.
The TRACE Register includes 7001 consecutive enzyme confirmed MIs in
6676 patients screened for entry into the trial. Medical history and compli-
cations of MI were obtained for all patients. Left ventricular systolic function
was determined by echocardiography in a core laboratory as wall motion
index (WMI) within 6 days of the infarction. Patients with WMI S 12 were
eligible for the study (corresponding to an ejection fraction below 35%) un-
less an exclusion criterion was present. Patients excluded were those not
tolerating or requiring an ACE inhibitor, those dying during screening phase
and those unwillinglunable to participate. Survival data were available for all
except 5 patients after 2-3 years.
The table shows number of MI and 1 year mortality in all patients, and
patients subgroubed by left ventricular systolic function. Also shown is pa-
tients with left ventricular dysfunction subgroubed by whether they were
randomised.
Conclusion: Even though the target population of high risk patients with
reduced left ventricular function was successfully identified, the final study
population had a 1 year mortality similar to unselected patients. This was
caused by exclusion of patients at extreme risk.
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1787-51 Systemic Effect of Ramipril on Endothelin, but not on
Eicosanoid Levels in Patients with Coronary Artery
Disease
Bernhard R. Winkelmann, Gerian Granefeld, Karen Nelson, Matti Verho,
Norbert Bender, Roland Kirsten, Wolfgang Schulz, Martin Kaltenbach. Johann
Wolfgang Goethe-University and Cardiovascular Research Hoechst and Cassella AG,
Frankfurt. Germany
Study aim: Neurohumoral effects of ramipril (R) alone or in combination with
isosorbide dinitrate (ISDN) compared to ISDN or placebo.
Study design: Placebo-controlled double-blind parallel group trial.
Methods: 32 patients with coronary artery disease (CAD) received placebo,
R 5 mg, ISDN 20 mg slow release b.Ld. or R + ISDN for one week. A 24 hour
kinetic profile of ramipril and its metabolite, of ace activity (ACE-A) and of re-
lated hormones (renin and aldosterone), of endothelin and of prostaglandins
(pG), thromboxane B2 {TXB2l. PGF2a, 6-keto PGF1 a, the stable metabolite of
prostacyclin (PGI2-M) was studied after the first dose. Measurements were
repeated after 8 days of treatment before and 3 hours after the morning
dose.
Results: Hormone measurements are presented as means of percent dif-
ference of patients treated with R (n = 16) vs. those without ace-inhibitor (n
= 16).
Time (hrs) a 1 2 3 4 6 8 24 Q-B 3-8
Ramipril(mgm a 8 5 4 3 2 1 0.4 1 7
Ramiprilat(mg/l) a 6 11 10 8 7 5 1 2 14
ACE-A(%) -6 -78 -95 -98 -98 -97 -96 -80 -82 -98
Aldosteron (%) 9 -5 -31 -34 -21 -27 -23 -34
Renin (%) -9 -7 7 19 13 17 53 32
Endothelin (%) -17 -13 -25 -19 -16 -15 -4 a
TXB2 (%) 4 10 4 5 5 a 12 -3
PGF2a 1%) 10 17 0 0 8 2 2 -9
PGI2-M(%) 7 a -3 8 -5 9 -1 -7 13
- = not done; significant differences are printed in italics (two-tailed t-test)
A single oral dose of 5 mg R reduced ACE activity (p < 0.001), decreased
aldosterone and increased renin (p < 0.1). R did not influence plasma levels
of the vasoconstricting (TXB2, PGF2al or vasodilating {pGI2-MI eicosanoid
mediators, but decreased endothelin (p < 0.1).
Conclusion: R, in a dose that results in significant systemic inhibition of the
renin angiotensin aldosteron system, does not induce measurable changes
of circulating eicosanoid concentrations, but seems to diminish systemic
release of endothelin.
11 :45
Hypotension Induced by Captopril in Patients with
Primary Autonomic Failure Occurs Independently of
Plasma Renin Levels and Sympathetic Nervous
Activity
J.S. Kooner 1, R. Baliga 1, WS. Peart, c.J. Mathias. 1Royal Postgraduate Medical
School, Hammersmith Hospital, London, UK.; St Mary's Hospital Medical School,
London, UK.
We have investigated the haemodynamic and hormonal responses to an-
giotensin converting enzyme inhibition in 12 patients with primary autonomic
failure (AF, 5 pure autonomic failure, 7 multiple system atrophy) and 7 nor-
mal subjects. Measurements of blood pressure (BP). heart rate (HR). stroke
distance (SO) and cardiac index (CI, continuous wave Doppler, forearm blood
flow (FBF, strain gauge plethysmography) and digital skin blood flow (DSBF,
laser Doppler flowmetry) were made non-invasively. Plasma renin activity
(PRA) and noradrenaline (NGRAD) were measured before and at 30 min in-
tervals after captopril (50 mg, oral).
Basal supine BP was higher in AF compared to normals (p < 0.05). After
captopril, mean BP fell in AF (117 ± 6 to 103 ± 5 mmHg, p < 0.05). but not in
normals (99 ± 4 to 97 ± 5 mmHg, ns). HR was unchanged after captopril in
both groups. The depressor response in AF was accompanied by a fall in SO
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(9.6 ± 1.2 to 7.6 ± 0.7 cm, p < 0.05) and in CI (676 ± 79 to 536 ± 65 cm/min,
p < 0.05). SO and Cl were unchanged after captopril in normals (SO, 7.7 ±
1.3 to 7.4 ± 0.6 cm; CI. 579 ± 117 to 571 ± 69 cm/min, both ns). There was
no reduction in forearm or digital skin vascular resistance after captopril in
either group. Basal PRA in AF was similar to normals, but did not rise after
captopril (691 ± 217 to 681 ± 221 pg/mllhr, ns), unlike normals (813 ± 103
to 1360 ± 290 pg/mllhr, p < 0.05). NORAO was unchanged after captopril in
both groups.
We conclude that. captopril lowers blood pressure in AF. unlike normals.
The depressor response in AF occurs independently of plasma renin levels
and sympathetic nervous activity, suggesting that alternative mechanisms,
including accumulation of bradykinin and prostaglandins, may be responsi-
ble.
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Conclusion: In severe CH F Six minute walk test is related to symptoms
and perceived exertion. The test also gives prognostic information and it is
related to functional classification.
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1788-31 Effect of Body Composition on Exercise Performance
in Patients with Heart Failure
John R. Wilson, Glenn Rayos, Jane Smith, Patricia Gothard, lK. Yeoh. VanderbJit
University; Nashville, TN
Changes in fat and skeletal muscle volume may contribute to the exercise in-
tolerance reported by patients with heart failure. To test this hypothesis, we
measured hemodynamic and ventilatory responses to exercise in 65 patients
with chronic heart failure. Body composition was determined by dual-energy
x-ray absorptiometry. Peak exercise V02 averaged 13.2 ± 2.9 ml/min/kg,
peak exercise cardiac index 4.5 ± 1.1 lImin/m2, lean body weight 55 ± 12 kg,
lean leg weight 17.2 ± 3.8 kg and total fat 27 ± 11 kg. Thirty-eight (58%) of
the patients were obese, as defined by a percentage fat >30%. Twenty-four
patients (37%) exhibited lean body wt/height <300 gm/cm, consistent with
muscle atrophy. Peak exercise V02 correlated closely with total leg muscle:
:... ...-----------,
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1788-1 I The 6-Minute Walk Test Predicts Maximal Oxygen
Consumption and Survival in Advanced Heart Failure
Lawrence P. Cahalin, Thomas G. Di Salvo, Michael M. Mathier, Dennis
M. McNamara, Marc J. Semigran, G. William Dec Massachusetts General Hospital,
Harvard Medical School, Boston, MA
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Although maximal oxygen consumption (MV02) is useful in predicting prog-
nosis and need for cardiac transplantation (TX) in patients with advanced
heart failure (HF), its determination requires sophisticated equipment. The
six-minute walk test (6-MW) is a simple indirect measure of functional capac-
ity, and predicts survival in moderate HE To assess the predictive value of the
6-MW, MV02, and percent predicted age-sex adjusted MV02 (%MV02) in
advanced HF, 45 pts (age 49 ± 8 yrs mean ± SO, LVEF 0.20 ± 0.06, RVEF 0.31
± 0.11) underwent cardiopulmonary exercise testing (cycle ergometry) and
the 6-MW during TX evaluation. Mean 6-MW distance ambulated was 310
± 100 meters, MV02 12.2 ± 4.5 ml/kg/min, and %MV02 38 ± 11 %. Multi-
variate analysis of patient characteristics, resting hemodynamics and 6-MW
(age, sex, weight, peak HR and BP during the 6-MW, right and left ventric-
ular ejection fraction, right atrial pressure, mean pulmonary artery pressure,
and cardiac index) identified distance ambulated during the 6-MW as the
strongest predictor of MV02 (p < 0.000) and %MV02 (p < 0.0001. In univari-
ate survival analysis, 6-MW > 300 meters predicted survival to the combined
end-point death or hospital admission for inotropic/mechanical support (IN)
as a bridge to TX (p < 0.05). but not overall survival (p = 0.075). In multivariate
proportional hazards survival analysis designed to compare %MV02, MV02,
and 6-MW, MV02 was selected as the best predictor of overall survival, and
%MV02 as the best predictor of IN-free survival. 6-MW was not selected in
any multivariate analysis. Conclusions: In pts with advanced HF evaluated
for TX, distance ambulated during the 6-MW predicts 1) MV02 and %MV02
and 2) IN-free survival but not overall survival. MV02 and %MV02 may be
superior to the 6-MW as predictors of survival in these pts: however, further
studies to es1ablish the prognostic utility of the 6-MW in pts with advanced
HF are warranted.
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Six Minute Walk Test Gives Prognostic Information in
Severe Hear Failure
Karl Swedberg, Robert M. Califf, Kirkwood Adams, Mlhai Gheorghiade, Frank
B. Harrel, William McKenna, Kenneth Schulman, Jorge Soler-Soler, Barry Uretsky,
F. Zannad, FIRST investigators. astra Hospital, G6teborg University; G6teborg,
Sweden
Distance walked in Six minute walk test (SMWTI has been shown to give
prognostic information in moderate heart failure. We studied the value of
SMWT in 359 patients with severe CHF (NYHA III-IV) in a multicenter trial of
continuous epoprostenol infusions. SMWT was performed in a 30 m long
corridor. Perceived symptoms were evaluated by the Borg scale. Follow up
was performed at 2 weeks, 1, 3, 6 and 9 months.
Results: SMWT at baseline was significantly related to survival (p =
0.0001). When SMWT distance was below median, 210 m, 6 month mor-
tality was 50% vs 20% above median (p < 0.001). Median Borg scale at end
of exercise was 3.2. A test with a Borg scale above median value was 174
m vs 230 m below median (p < 0.001). When all tests performed at baseline
and during follow up were included (n = 1291) and related to changes in
NYHA class, there was a significant relationship to NYHA class (p = 0.0001).
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There was no relationship between V02/9m leg muscle and the lean body
wt/height index. suggesting that muscle atrophy does not affect muscle per-
formance/unit of muscle. V02/kg muscle was higher in obese vs non-obese
patients (72 + 14 vs 59 + 13 mllmin/kg (p < 0.01) whereas peak V02/kg body
weight was similar (13.0 + 3.3 vs 13.2 + 2.6 mllmin/kg). since body weight
inCludes fat. These findings suggest that skeletal muscle volume influences
exercise capacity in patients with heart failure. Exercise capacity in obese
patients is underestimated by normalizing for body weight.
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1788-41 Does Low Level Training Increase Peak Aerobic
Capacity in Patients with Congestive Heart Failure?
Laura Demopoulos, Rachel Bijou. Icilma Fergus, Marco Gentilucci,
Leslie Panzarino, Margaret Jones, Marie Galvao, Edmund H. Sonnenblick, Thierry
H. LeJemtel. Albert Einstein College ofMedicine, Bronx, New York
Conventional high level exercise training at a workload consistent with 75%
of peak oxygen consumption (pV02, ml/min/kg) in patients with congestive
heart failure (CHF) improves peak aerobic capacity and limb vasodilatory ca-
pacity. However, training at this workload may promote left ventricular dilata-
tion in patients with CHF by prolonged exposure to substantially elevated
filling pressure (PCWP). Whether training at low level, I.e.. at a workload con-
sistent with <50% pV02, would result in limited increases in PCWP while
still improving peak aerobic capacity and peripheral vasodilatory function is
unknown. Accordingly, 15 patients with stable advanced CH F underwent
measurement of 1) the PCWP response to low vs high level exercise, and
2) the change in peak aerobic capacity and limb vasodilatory capacity re-
SUlting from participation in a low level training program. PCWP was mea-
sured by right heart catheterization at rest, and during low and high level
exercise. Patients then performed 12 weeks of low level training, utilizing a
semi-recumbent bicycle. Pre- and post-training evaluations included pV02,
calf and forearm peak hyperemic blood flow (PHBF, ml/min/1 00 mil. and rest-
ing heart rate (HR, bIminI.
Results: 1)PCWP rose to 20 mmHg during low level exercise (t..54% vs
rest), and 34 mmHg during high level exercise (t..162% vs rest). 2)Pre- and
post-training data are as follows:
pV02 calf PHBF forearm PHBF HR
pre~train 99 1B 23 99
post~train 14.1 36 20 BO
p value 0.02 <0.01 NS 002
Conclusions: 1) The rise in PCWP is significantly less during low level exer-
cise than during high level exercise. 2) Training at a workload consistent with
550% of pV02 significantly improves peak aerobic capacity. 3) PHBF in the
trained calf increases 100% from baseline, while it does not change in the
untrained forearm. Enhanced vasodilatory responses in exercising muscle
